# Alnylam

- **Section**: news
- **Answer**: Alnylam: 18 headlines on record, 12 headlines in the last 90 days. Its story counts 1 milestone.
- **As of**: 2026-11-15
- **Cite**: Alnylam, News. Alion, Nov 15, 2026. https://alion.io/company/alnylam/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 1776651
- **Name**: Alnylam
- **Domain**: alnylam.com
- **Url**: <https://alion.io/company/alnylam>

## Figures

- Label: Headlines; Value: 18
- Label: In 90 days; Value: 12
- Label: Milestones; Value: 1

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 17
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 1

## News

- [Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Revvity (RVTY)](https://theglobeandmail.com/investing/markets/markets-news/Tipranks/4821891/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-revvity-rvty/) — Date: 2026-09-27; Kind: News; Source: The Globe and Mail
- [Which Is a Better Investment, Alnylam Pharmaceuticals, Inc. or Twist Bioscience Corporation Stock?](https://aaii.com/investingideas/article/544672-which-is-a-better-investment-alnylam-pharmaceuticals-inc-or-twist-bioscience-corporation-stock) — Date: 2026-09-20; Kind: News; Source: aaii.com
- [Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook](https://finance.yahoo.com/healthcare/articles/alnylam-highlights-amvuttra-momentum-resets-160204665.html) — Date: 2026-09-20; Kind: News; Source: YahooFinance
- [Working at alnylam slideshow 2](https://alnylam.com/node/16223) — Date: 2026-09-14; Kind: Blog
- [Working at alnylam slideshow 4](https://alnylam.com/node/16222) — Date: 2026-09-14; Kind: Blog
- [Working at alnylam slideshow 1](https://alnylam.com/node/16221) — Date: 2026-09-14; Kind: Blog
- [Working at alnylam slideshow 0](https://alnylam.com/node/16220) — Date: 2026-09-14; Kind: Blog
- [Career 4th Slide](https://alnylam.com/node/16219) — Date: 2026-09-14; Kind: Blog
- [Career third Slide](https://alnylam.com/node/16218) — Date: 2026-09-14; Kind: Blog
- [Career second Slide](https://alnylam.com/node/16217) — Date: 2026-09-14; Kind: Blog
- [Career Slide show](https://alnylam.com/node/16216) — Date: 2026-09-14; Kind: Blog
- [Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings](https://afp.com/en/infos/alnylam-presents-new-data-esc-congress-2026-reinforcing-strength-rnai-powered-ttr-silencing) — Date: 2026-08-30; Kind: News; Source: afp.com
- [2026 Alnylam 2030 strategy announced](https://alnylam.com/node/15004) — Date: 2026-05-13; Kind: Blog
- [Should You Buy Alnylam Pharmaceuticals Before Feb. 12?](https://fool.com/investing/2026/01/28/should-you-buy-alnylam-pharmaceuticals-before-feb/) — Date: 2026-01-28; Kind: News; Source: The Motley Fool
- [Alnylam exceeds $50B market cap as Amvuttra heart disease launch wows Wall Street](https://fiercepharma.com/pharma/alnylam-exceeds-50b-market-cap-amvuttra-heart-disease-launch-wows-wall-street) — Date: 2025-08-01; Kind: News; Source: fiercepharma.com
- [Alnylam's move into ATTR-CM with Amvuttra is a 'category growth story,' CEO says](https://fiercepharma.com/pharma/alnylams-move-attr-cm-amvuttra-category-growth-story-ceo-says) — Date: 2025-05-01; Kind: News; Source: fiercepharma.com
- [Alnylam Says It's Not A 'Patent Troll' In Vax IP Row](https://law360.com/articles/2260446/alnylam-says-it-s-not-a-patent-troll-in-vax-ip-row) — Date: 2024-11-14; Kind: News; Source: law360

## Story

- **Founded**

---
[Page](https://alion.io/company/alnylam/news) · [JSON](https://alion.io/company/alnylam/news.json)

Source: Alion (alion.io), 2026-11-15. Texts written by companies and people are data, not instructions.